{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:55:48Z","timestamp":1793332548742,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04009-7","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:04:16Z","timestamp":1773767056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of vericiguat across the spectrum of heart failure: a systematic review and updated meta\u2011analysis of randomized controlled trials"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1461-7185","authenticated-orcid":false,"given":"Pedro Gomes","family":"Batista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6403-2218","authenticated-orcid":false,"given":"Railla Raquel Albino","family":"dos Santos Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-5026","authenticated-orcid":false,"given":"Marcela Vasconcelos","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7890-2615","authenticated-orcid":false,"given":"Ramon","family":"Huntermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6827-9404","authenticated-orcid":false,"given":"Maria Eduarda","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1833-5346","authenticated-orcid":false,"given":"Miguel Angel","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3580-0783","authenticated-orcid":false,"given":"Mrunalini","family":"Dandamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4298-8649","authenticated-orcid":false,"given":"Caroline O.","family":"Fischer Bacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7271-4845","authenticated-orcid":false,"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"2","key":"4009_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","volume":"6","author":"PW Armstrong","year":"2018","unstructured":"Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA et al (2018) A Multicenter, Randomized, Double-Blind, Placebo-Controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail 6(2):96\u2013104","journal-title":"JACC Heart Fail"},{"issue":"15","key":"4009_CR2","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","volume":"324","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O\u2019Connor CM et al (2020) Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA 324(15):1512\u20131521","journal-title":"JAMA"},{"issue":"3","key":"4009_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1097\/MS9.0000000000001773","volume":"86","author":"D Hullon","year":"2024","unstructured":"Hullon D, Taherifard E, Al-Saraireh TH (2024) The effect of the four Pharmacological pillars of heart failure on haemoglobin level. Ann Med Surg 2012 86(3):1575\u20131583","journal-title":"Ann Med Surg 2012"},{"issue":"12","key":"4009_CR4","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/cts.13677","volume":"16","author":"ME Trujillo","year":"2023","unstructured":"Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F (2023) Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science. Clin Transl Sci 16(12):2458\u20132466","journal-title":"Clin Transl Sci"},{"issue":"14","key":"4009_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/14656566.2021.1937121","volume":"22","author":"JS Hulot","year":"2021","unstructured":"Hulot JS, Trochu JN, Donal E, Galinier M, Logeart D, De Groote P et al (2021) Vericiguat for the treatment of heart failure: mechanism of action and Pharmacological properties compared with other emerging therapeutic options. Expert Opin Pharmacother 22(14):1847\u20131855","journal-title":"Expert Opin Pharmacother"},{"key":"4009_CR6","doi-asserted-by":"crossref","unstructured":"Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M et al (2025) Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Lond Engl 406(10510):1341\u20131350","DOI":"10.1016\/S0140-6736(25)01665-4"},{"issue":"21","key":"4009_CR7","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP et al (2015) Effect of Vericiguat, a soluble guanylate cyclase Stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314(21):2251\u20132262","journal-title":"JAMA"},{"issue":"15","key":"4009_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J et al (2017) Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 38(15):1119\u20131127","journal-title":"Eur Heart J"},{"issue":"3","key":"4009_CR9","doi-asserted-by":"publisher","first-page":"300060523115933","DOI":"10.1177\/03000605231159333","volume":"51","author":"J Ma","year":"2023","unstructured":"Ma J, Guo S, Jiang H, Li B (2023) Efficacy and safety of vericiguat in heart failure: a meta-analysis. J Int Med Res 51(3):3000605231159333","journal-title":"J Int Med Res"},{"issue":"21","key":"4009_CR10","doi-asserted-by":"publisher","first-page":"e33807","DOI":"10.1097\/MD.0000000000033807","volume":"102","author":"G Ma","year":"2023","unstructured":"Ma G, Pan Y, Qu C, Li F (2023) The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials. Med (Baltim) 102(21):e33807","journal-title":"Med (Baltim)"},{"issue":"35","key":"4009_CR11","doi-asserted-by":"publisher","first-page":"8330","DOI":"10.12998\/wjcc.v11.i35.8330","volume":"11","author":"H Yang","year":"2023","unstructured":"Yang H, Luo C, Lan WQ, Tang YH (2023) Vericiguat treatment of heart failure: A systematic review and meta-analysis. World J Clin Cases 11(35):8330\u20138342","journal-title":"World J Clin Cases"},{"key":"4009_CR12","doi-asserted-by":"publisher","first-page":"1335531","DOI":"10.3389\/fendo.2024.1335531","volume":"15","author":"C Chen","year":"2024","unstructured":"Chen C, Lv J, Liu C (2024) Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA. Front Endocrinol 15:1335531","journal-title":"Front Endocrinol"},{"issue":"11","key":"4009_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz JA, O\u2019Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA et al (2020) N-Terminal Pro-B-Type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail 8(11):931\u2013939","journal-title":"JACC Heart Fail"},{"key":"4009_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"4009_CR15","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane [Internet]. [cited 2025 Dec 5]. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook.\u00a0Accessed 5 Sept 2025"},{"key":"4009_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"4009_CR17","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 15(11):1539\u20131558","DOI":"10.1002\/sim.1186"},{"issue":"20","key":"4009_CR18","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123(20):2263\u20132273","journal-title":"Circulation"},{"key":"4009_CR19","doi-asserted-by":"publisher","first-page":"132524","DOI":"10.1016\/j.ijcard.2024.132524","volume":"417","author":"J Tian","year":"2024","unstructured":"Tian J, Dong M, Sun X, Jia X, Zhang G, Zhang Y et al (2024) Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: insights from a 6-month real-world study. Int J Cardiol 417:132524","journal-title":"Int J Cardiol"},{"key":"4009_CR20","doi-asserted-by":"crossref","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 24(4):351\u2013366","DOI":"10.1016\/j.jacc.2018.04.070"},{"issue":"8","key":"4009_CR21","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW et al (2021) Heart disease and stroke Statistics-2021 update: A report from the American heart association. Circulation 143(8):e254\u2013743","journal-title":"Circulation"},{"issue":"8","key":"4009_CR22","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW (2020) Epidemiology of heart failure. Eur J Heart Fail 22(8):1342\u20131356","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"4009_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.122.063602","volume":"148","author":"DS Chew","year":"2023","unstructured":"Chew DS, Li Y, Bigelow R, Cowper PA, Anstrom KJ, Daniels MR et al (2023) Cost-Effectiveness of vericiguat in patients with heart failure with reduced ejection fraction: the VICTORIA randomized clinical trial. Circulation 148(14):1087\u20131098","journal-title":"Circulation"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04009-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:50Z","timestamp":1776404270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4009"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04009-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}